News und Analysen
SCHMID Group Q4 Earnings Call Highlights
Key Points
- Interested in SCHMID Group N.V.? Here are five stocks we like better.
- SCHMID Group expects stronger demand in 2026 as AI infrastructure, optical modules, and advanced packaging
ReNew Energy Global Q4 Earnings Call Highlights
Key Points
- Interested in ReNew Energy Global PLC? Here are five stocks we like better.
- ReNew Energy Global said fiscal 2026 was its strongest year yet, with operating portfolio capacity rising
Compugen Q1 Earnings Call Highlights
Key Points
- Interested in Compugen Ltd.? Here are five stocks we like better.
- COM701 ovarian trial is on schedule: Compugen said all sites are open and enrolling in its MAIA-ovarian study, and
Revolution Medicines Aktie: Truist startet mit 179-Dollar-Ziel
Revolution Medicines setzt auf Angriff im Kampf gegen RAS-mutierte Krebsarten. Während das Unternehmen seine…
Der Beitrag Revolution Medicines Aktie: Truist startet mit 179-Dollar-Ziel erschien
iRhythm Technologies Touts Medicare Win, Zio Growth and AI-Driven Margin Gains
Key Points
- Interested in iRhythm Technologies? Here are five stocks we like better.
- iRhythm said a favorable Medicare local coverage determination expanded access for its services, while the
Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference
Key Points
- Interested in Ionis Pharmaceuticals, Inc.? Here are five stocks we like better.
- Ionis Pharmaceuticals said TRYNGOLZA could become a more than $3 billion U.S. product in severe
Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus
Key Points
- Interested in Insmed, Inc.? Here are five stocks we like better.
- Insmed defended the BRINSUPRI launch after investors worried about discontinuation rates, saying the drug’s $208
Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build
Key Points
- Interested in Incyte Corporation? Here are five stocks we like better.
- Incyte’s CEO says the company’s post-Jakafi growth path is becoming clearer as its commercial business
Sonova erzielt 2025/26 ein starkes Ergebnis, wächst schneller als der Markt und steigert die Profitabilität
Integra LifeSciences Says Transformation Is Working as SurgiMend Relaunch Nears
Integra LifeSciences (NASDAQ:IART) is keeping its core strategy intact following a leadership change that returned Stuart to the roles of chairman and chief
GRAIL Says Galleri Demand Is Rising as NHS Talks, FDA Review Move Ahead
GRAIL (NASDAQ:GRAL) said demand for its Galleri multi-cancer early detection test has continued to grow despite recent headlines related
Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline
Gilead Sciences (NASDAQ:GILD) Chief Commercial Officer and Head of Corporate Affairs Johanna Mercier said the company is leaning on its HIV business
GE HealthCare Technologies Sticks to Growth Story After Inflation-Driven Guidance Cut
GE HealthCare Technologies (NASDAQ:GEHC) executives said the company remains confident in its long-term growth prospects despite a
Valneva Aktie: VLA15 zeigt über 70 Prozent Wirksamkeit
Der französische Impfstoffhersteller Valneva startet mit einer gemischten Bilanz in die neue Handelswoche. Die…
Der Beitrag Valneva Aktie: VLA15 zeigt über 70 Prozent Wirksamkeit erschien zuerst auf
Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference
Erasca (NASDAQ:ERAS) executives said the company sees multiple potential development paths for its RAS-targeting portfolio, highlighting early clinical activity for ERAS-0015 in lung, pancreatic
DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day
DexCom (NASDAQ:DXCM) used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for
Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval
Denali Therapeutics (NASDAQ:DNLI) is seeing early commercial interest for its first approved drug, AVLAYAH, following its March 24
DRI Healthcare Trust Q1 Earnings Call Highlights
DRI Healthcare Trust (TSE:DHT.UN) reported higher first-quarter income and expanded margins as management said the royalty investment company continued to benefit from its post-internalization cost
Calian Group Q2 Earnings Call Highlights
Calian Group (TSE:CGY) reported record second-quarter revenue and sharply higher adjusted EBITDA, with management pointing to accelerating demand in defense and space markets, improved execution
DocGo Targets Profitability as It Pivots to Mobile Health, Medical Transport
DocGo (NASDAQ:DCGO) Chief Executive Officer Lee Bienstock outlined the company’s transition away from COVID-related, migrant and emergency-response
BioStem Technologies Q1 Earnings Call Highlights
BioStem Technologies (OTCMKTS:BSEM) said its first quarter of 2026 marked a major shift in its business model following a late-January acquisition that moved the company’s focus from physician
Stereotaxis Q1 Earnings Call Highlights
Stereotaxis (NYSEAMERICAN:STXS) said its first-quarter results did not yet reflect what management described as a major commercial transition
CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms
CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the
Pelthos Therapeutics Q1 Earnings Call Highlights
Pelthos Therapeutics (NYSEAMERICAN:PTHS) reported higher first-quarter revenue as prescriptions for its lead product, ZELSUVMI, continued to grow in the treatment’s third full quarter since launch